Icovamenib for Healthy Volunteers
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial explores how the body absorbs a new treatment called icovamenib under different food conditions. The study tests icovamenib with a low-fat breakfast, a high-fat breakfast, or on an empty stomach. Healthy individuals not on medication and with a BMI between 18 and 27 might be suitable for this trial. Participants will help researchers understand how food affects icovamenib's effectiveness and safety. As a Phase 1 trial, this research focuses on understanding how the treatment works in people, offering participants the opportunity to be among the first to receive it.
Will I have to stop taking my current medications?
Yes, you will need to stop taking any prescribed or over-the-counter drugs or herbal remedies (except for hormonal replacement therapy, hormonal contraception, and up to 4 grams per day of acetaminophen) at least 14 days before starting the study medication.
Is there any evidence suggesting that this trial's treatments are likely to be safe?
Research has shown that icovamenib has been well-tolerated in previous studies. One study found icovamenib to be safe over a year-long period, with participants experiencing no serious side effects. Another study confirmed these results, indicating that icovamenib was safe and well-tolerated.
There is less direct information about icovamenib HPMC. However, since icovamenib itself has demonstrated good safety, it suggests that icovamenib HPMC might also be safe. This trial is in its early phase, marking the first step in understanding how the body reacts to these treatments. Researchers are studying both forms of the treatment to ensure their safety for people.12345Why are researchers excited about this trial's treatments?
Researchers are excited about icovamenib and its HPMC variant because they offer a potentially new way to manage conditions that require targeted therapies, especially given the flexibility in administration relative to meal timing and composition. Unlike existing standard treatments that may not account for these variables, icovamenib is being explored in various regimens, including fasted states and different meal types, which could optimize its absorption and effectiveness. The HPMC version, in particular, might provide a unique formulation that enhances delivery and efficacy, potentially offering more consistent therapeutic outcomes. This trial aims to uncover whether these variations make a significant difference in how the body processes the drug, which could lead to more personalized treatment approaches.
What evidence suggests that this trial's treatments could be effective?
This trial will study different regimens of icovamenib in healthy volunteers. Research has shown that icovamenib may improve conditions like severe insulin-deficient diabetes. In earlier studies, patients experienced a 1.2% drop in HbA1c levels, which indicate blood sugar, over a year. This improvement persisted even nine months after stopping the treatment. Additionally, icovamenib has helped control blood sugar and support weight loss when combined with other treatments. These findings suggest that icovamenib could be an effective treatment option.15678
Who Is on the Research Team?
Biomea Fusion Inc.
Principal Investigator
Biomea Fusion Inc.
Are You a Good Fit for This Trial?
Healthy volunteers who understand the study, will follow its rules, have a BMI of 18.0-27.0 kg/m2, normal blood sugar levels, and are not pregnant or breastfeeding can join. People with heart issues, abnormal lab results, liver problems, certain infections like HIV/HBV/HCV or a family history of specific tumors cannot participate.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive a single dose of icovamenib capsule in various fed and fasted states to assess food effect and PK profile
Follow-up
Participants are monitored for safety and effectiveness after treatment, including PK profile and safety assessments
What Are the Treatments Tested in This Trial?
Interventions
- Icovamenib
- Icovamenib HPMC
Trial Overview
The trial is testing how food affects the body's response to two forms of icovamenib (a drug in capsule form), using an open-label design where everyone knows what treatment they're getting. Participants will try both versions at different times to compare effects.
How Is the Trial Designed?
9
Treatment groups
Experimental Treatment
I - icovamenib HPMC capsule 100mg in the fed state (1 h after initiation of a low-fat breakfast)
H - icovamenib HPMC capsule 100mg in the fed state (0.5 h after initiation of a low-fat breakfast)
G - icovamenib HPMC capsule 100mg in the fed state (1h after initiation of a high-fat breakfast)
F - icovamenib HPMC capsule 100mg in the fed state (0.5 h after initiation of a high-fat breakfast)
E - icovamenib capsule 100mg in the fed state (1 h after initiation of a high-fat breakfast)
D - icovamenib capsule 100mg in the fed state (0.5 h after initiation of a high-fat breakfast)
C - icovamenib capsule 100mg in the fed state (1 h after initiation of a low-fat breakfast)
B - icovamenib capsule 100mg in the fed state (0.5 h after initiation of low-fat breakfast)
A - icovamenib capsule 100mg in fasted state
Find a Clinic Near You
Who Is Running the Clinical Trial?
Biomea Fusion Inc.
Lead Sponsor
Citations
1.
investors.biomeafusion.com
investors.biomeafusion.com/news-releases/news-release-details/biomea-fusion-announces-positive-52-week-results-phase-iiBiomea Fusion Announces Positive 52-Week Results from ...
Icovamenib showed a sustained treatment benefit at Week 52 (9 months past the end of treatment) in the severe insulin-deficient diabetes ...
2.
clinicaltrials.gov
clinicaltrials.gov/study/NCT07254286?aggFilters=status%3A%2CfunderType%3AindustryNCT07254286 | Food Effect Study in Healthy Volunteers
This study is designed to evaluate the effect of meal time and fat content of food on the PK and safety of the icovamenib capsule and the icovamenib ...
Biomea Fusion Announces Positive 52-Week Results from ...
Among these severe insulin-deficient patients, icovamenib achieved a durable HbA1c reduction of 1.2% (p=0.01) sustained through Week 52. The ...
Biomea Fusion Presents New Preclinical and Clinical Data ...
The studies presented at ADA demonstrate that icovamenib enhanced glycemic control and drove additional weight loss when used in combination with GLP-1 ...
Biomea Fusion Presents Data Demonstrating Enhanced ...
In a rodent model of T2D, icovamenib in combination with low-dose semaglutide promoted enhanced glycemic control and body weight reduction ...
6.
medchemexpress.com
medchemexpress.com/menin-mll-inhibitor-21.html?srsltid=AfmBOorftocExL9GMIvUutiucTdLVljeMVpWscdVtCXwgtnvK_x7Xa4bIcovamenib (BMF-219) | Menin-MLL Inhibitor
Icovamenib (BMF-219) is a selective, orally active, irreversible Menin inhibitor. Icovamenib forms a stable and irreversible covalent bond with Menin.
EX-99.1
Overall, icovamenib was well tolerated and demonstrated a favorable safety profile in the COVALENT-111 study. The company used clinical ...
8.
investors.biomeafusion.com
investors.biomeafusion.com/news-releases/news-release-details/biomea-fusion-reports-new-preclinical-data-icovamenibBiomea Fusion Reports New Preclinical Data on Icovamenib ...
Validated Safety. Icovamenib in combination with semaglutide was well tolerated across multiple time points. “We believe these preclinical ...
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.